GLP-1 medications such as Ozempic have reshaped treatment for Type 2 diabetes. These drugs can help patients manage blood sugar, lower cardiovascular risk, and, in many cases, lose a substantial amount of weight.
But researchers are still trying to determine whether those physical health improvements also extend into other parts of life, such as mental health, relationships, and employment.
A new National Bureau of Economic Research working paper from University of Chicago Harris School of Public Policy economist Robert Kaestner and coauthor Cuiping Schiman examined that question. Among adults with diabetes, the researchers found little evidence that using GLP-1 medications produced measurable changes in mental health, self-rated health, employment, or marital status.
“We know these drugs improve health outcomes, and there’s been a great deal of research documenting those benefits,” said Kaestner, a research professor. “What hadn’t really been examined was whether those improvements extended into other parts of people’s lives.”
Looking Beyond Physical Health
The issue is becoming increasingly important as insurers and government programs consider whether to broaden access to GLP-1 medications. Their medical benefits are already well documented, but it is less clear whether the drugs also produce social or economic gains that could add to the argument for wider coverage.
To investigate, Kaestner and Schiman studied more than 10 years of data from the nationally representative Medical Expenditure Panel Survey. Their analysis focused on adults with diabetes between 2012 and 2023.
Instead of only comparing people who used GLP-1 medications with those who did not, the researchers followed the same individuals over time. This allowed them to look at whether a person’s circumstances changed after starting treatment.
They examined several indicators of well-being, including depression symptoms, psychological distress, self-rated health, employment, and marital status.
At first, GLP-1 users appeared to differ from non-users in some areas, including employment and marriage. However, those differences mostly disappeared when the researchers looked at changes within the same individuals over time.
That pattern suggests the original gaps may have reflected differences between the types of people who used GLP-1 drugs and those who did not, rather than effects caused by the medications themselves.
Few Measurable Changes Outside Health
The results were similar whether the researchers looked at people after roughly one year of GLP-1 use or followed them over a longer, two-year period.
In both cases, they found little evidence that taking the medications led to meaningful changes in the broader life outcomes they measured.
Kaestner emphasized that this does not prove GLP-1 drugs have no effects outside physical health. Some changes may simply be more subtle or more difficult to capture with the measures used in the study.
“We measured outcomes like whether someone became employed or unemployed, whether they got married or divorced, and standard indicators of mental health,” he said. “Those are important measures, but they don’t necessarily capture changes in self-esteem, relationship quality, or other day-to-day experiences.”
Medical Benefits Remain Well Established
The researchers also stressed that the findings do not call the medical value of GLP-1 medications into question.
For adults with diabetes, Kaestner said, the clearest measurable benefits remain those already demonstrated in clinical research, including improved glycemic control, weight loss, and better physical health.
As GLP-1 medications become more widely used beyond diabetes and increasingly common for weight management, researchers will have more opportunities to study whether broader social effects emerge in other groups or over longer periods.
“This is still a very new area of research,” he said. “As use continues to grow, understanding these broader consequences will become increasingly important for patients, clinicians, and policymakers alike.”
